Dermatology 2017-09-25T19:21:47+00:00

Our Work in Dermatology

Targeted biologics, the recent emergence of innovative new oral therapies and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed. Targeted biologics, the recent emergence of innovative new oral therapies and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed.

VIEW REPORTS OFFERED IN THIS AREA

Diseases Covered

Atopic Dermatitis, Psoriasis

Board of Advisors

Coming soon.

Advocacy Groups

The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with diseases in dermatology and those who are close to them.

RECENT PUBLICATIONS

Early Launch Metrics for Janssen’s Tremfya May Lag Those of Lilly’s Taltz at a Similar Post-Launch Period, but Signs Indicate the New IL-23 Inhibitor is Poised to Set a New Bar for Efficacy in Skin – September 14, 2017
>VIEW ARTICLE

Uptake of Sanofi/Regeneron’s Dupixent for Atopic Dermatitis Strong, but Sales Representative Contact Rates Leave Something to be Desired – August 21, 2017
>VIEW ARTICLE

Janssen’s Tremfya (guselkumab) Makes its Debut in the Psoriasis Market and Early Dermatologist Feedback Reveals that Distinction from Stelara and the IL-17 Inhibitors will be Key to Success – August 9, 2017
>VIEW ARTICLE

UPCOMING CONFERENCES

Fall Clinical Dermatology Conference
>LEARN MORE

HELPFUL LINKS